World Neurosurgery Publishes New Clinical Study Performed at the Walter Reed National Military Medical Center Showing Positive Performance of Vycor's VBAS in the Treatment of Wartime Brain Injuries

Aug 12, 2015, 10:10 ET from Vycor Medical, Inc.

BOCA RATON, Fla., Aug. 12, 2015 /PRNewswire/ -- Vycor Medical, Inc. (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported that a new study of its ViewSite™ Brain Access System (VBAS) clinical performance in treatment of brain injuries, entitled "Use of Minimally Invasive Retractor System for Retrieval of Intracranial Fragments in Wartime Trauma," has been recently published in World Neurosurgery.

The study, at the Walter Reed National Military Medical Center, was designed to explore whether the use of VBAS, a tubular retractor device, offered a valid and safe option for treatment of wartime penetrating brain injuries that resulted in deep-seated fragments, including shrapnel, bullets, and bone. Mechanism of injury was gunshot wound to the head and fragmentation injury to the head from improvised explosive devices. VBAS was used to facilitate removal of all the intraventricular or deep parenchymal fragments. Patients were aged 21-29 years of age.

The surgeons used VBAS in multiple different manners, depending on the depth, location and type of pathology being accessed. In all cases, the fragment was successfully removed. No patient had worsening of their neurological condition following surgery. The study concluded that deep parenchymal and intraventricular fragments can be safely removed using VBAS.

"This high-quality clinical study evidences the clinical superiority of VBAS, which in turn drives its adoption and accelerates the hospital approval process," said Peter Zachariou, CEO of Vycor. "There have now been eight peer-reviewed studies published on VBAS and numerous papers evidencing its clinical advantages which represent important steps towards VBAS becoming the standard of care for brain retraction and access."

The study follows four studies published earlier this year, including one published in the prestigious Journal of Neurosurgery that also featured VBAS on the front cover. VBAS clinical studies are available here.

About Walter Reed National Military Medical Center

Walter Reed National Military Medical Center is part of the Department of Defense and is one of the most prominent U.S. military medical centers in the U.S., having served numerous U.S. presidents since the 20th century.

About World Neurosurgery

World Neurosurgery is the official journal of the World Federation of Neurosurgical Societies, a professional, scientific, non-governmental organization representing some 30,000 neurosurgeons worldwide. World Neurosurgery is recognized as not only conveying high-level peer reviewed clinical and laboratory neuroscience, but also to address issues of educational relevance.

About ViewSite™ Surgical Access Systems (VBAS)

Vycor Medical's ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. For an overview of VBAS, see VBAS Video or visit www.vycorvbas.com.

About Vycor Medical, Inc.

Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

Vycor is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea and Japan and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam.

For the latest information on the company, including media and other coverage, and to learn more, visit www.vycormedical.com, www.vycorvbas.com or www.novavision.com.     

Investor Relations:
Liolios Group, Inc.
Ronald A. Both
Tel +1-949-574-3860
vyco@liolios.com

SOURCE Vycor Medical, Inc.



RELATED LINKS

http://www.vycormedical.com